exa-cel治疗输血依赖型β地中海贫血后无效造血纠正与铁稳态正常化
exa-cel是一种一次性CRISPR-Cas9基因编辑细胞疗法,获批用于12-35岁输血依赖型β地中海贫血(TDT)患者。3期CLIMB THAL-111研究显示exa-cel再激活胎儿血红蛋白,91%参与者实现输血独立。本文报告exa-cel对无效造血和铁稳态指标的影响,截至2025年4月数据cut,98%参与者(55/56)输血独立≥12个月,38例(68%)停止祛铁治疗,红铁酮下降、铁调素正常化,铁过载标志物下降并稳定。
要点
- exa-cel治疗后98%参与者输血独立≥12个月,68%停止祛铁治疗。
- 红铁酮浓度下降、铁调素水平正常化,提示无效造血纠正和铁稳态恢复。
- 铁蛋白、肝铁浓度和心脏T2*下降后保持稳定,即使停止祛铁治疗。
核心结论
- exa-cel infusion restores effective erythropoiesis and iron homeostasis in TDT patients achieving transfusion independence after fetal hemoglobin reactivation.
研究设计与样本
- Phase 3 study CLIMB THAL-111 and long-term follow-up CLIMB-131; 56 participants; data cut April 2025.
主要发现
- 98% of participants (55 of 56) were transfusion independent for ≥12 months.
- 38 participants (68%) discontinued iron removal therapy; mean duration off therapy 19.4 months.
- Erythroferrone concentrations decreased and hepcidin levels normalized in all participants.
- Improvements and trends toward normalization in erythropoietin levels, reticulocyte counts, and soluble transferrin receptor concentrations.
- Ferritin, liver iron concentration, and cardiac T2* decreased and then remained stable throughout follow-up, even after cessation of iron removal therapy.
临床怎么用
- exa-cel可考虑用于12-35岁输血依赖型β地中海贫血患者,以实现输血独立并纠正无效造血和铁稳态。
- 治疗后输血独立且停祛铁治疗者,铁过载标志物仍可维持稳定,支持持续监测下安全停用祛铁治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Exagamglogene autotemcel (exa-cel) is a one-time, ex vivo, CRISPR-Cas9 gene edited cell therapy approved for patients with transfusion dependent β-thalassemia (TDT) aged 12-35 years. In a Phase 3 study (CLIMB THAL-111), exa-cel treatment resulted in reactivation of fetal hemoglobin and increases in total hemoglobin, leading to transfusion independence in 91% of participants. Here, we report on the impact of exa-cel treatment on measures of ineffective erythropoiesis and iron homeostasis, which were secondary and exploratory endpoints in CLIMB THAL-111 and the CLIMB-131 long-term follow-up study. Prior to exa-cel infusion, all participants were receiving regular red blood cell transfusions and iron chelation therapy. At time of data cut (April 2025), 98% of participants (55 of 56) had been transfusion independent for ≥ 12 months and 38 (68%) had discontinued iron removal therapy (mean duration off iron removal therapy 19.4 months). Following transfusion independence and cessation of iron removal therapy, erythroferrone concentrations decreased and hepcidin levels normalized in all participants, indicating correction of ineffective erythropoiesis and restoration of iron homeostasis. Further supporting this finding, improvements and trends toward normalization were seen in key erythropoiesis biomarkers, including erythropoietin levels, reticulocyte counts, and soluble transferrin receptor concentrations. Iron overload biomarkers, including ferritin, liver iron concentration, and cardiac T2*, decreased and then remained stable throughout follow-up, even after cessation of iron removal therapy. These results demonstrate restoration of effective erythropoiesis and iron homeostasis after exa-cel infusion in the setting of transfusion independence following reactivation of fetal hemoglobin. (CLIMB THAL-111 and CLIMB-131; Clinical Trials.gov numbers NCT03655678 and NCT04208529).
引用
- Sheth S, Corbacioglu S, de la Fuente J, et al. Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia. Am J Hematol. 2026. PMID: 42252696. doi:10.1002/ajh.70382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。